Multiple Sclerosis

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Register here to gain access to SAGE's 500+ Journals Online

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
1352458506070732v1
13/2/256    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Papeix, C
Right arrow Articles by Gout, O
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Papeix, C
Right arrow Articles by Gout, O
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
This version was published on March 1, 2007
Multiple Sclerosis, Vol. 13, No. 2, 256-259 (2007)
DOI: 10.1177/1352458506070732

Immunosuppressive therapy is more effective than interferon in neuromyelitis optica

C Papeix

Department of Neurology, Hôpital de la Salpêtrie`re, Paris, France, caroline.papeix{at}psl.ap-hop-paris.fr

J-S Vidal

Institut National de la Santé et de la Recherche Médicale Unité 708, Hôpital de la Salpêtrie`re, Paris, France

J de Seze

Department of Neurology, CHU de Lille, Lille, France

C Pierrot-Deseilligny

Department of Neurology, Hôpital de la Salpêtrière, Paris, France

A Tourbah

Department of Neurology, Hôpital de la Salpêtrie`re, Paris, France, Department of Internal Medicine, CHNO XV/XX, Paris, France

B Stankoff

Department of Neurology, Hôpital de la Salpêtrie`re, Paris, France, Centre d’Investigation Clinique, Hôpital de la Salpêtrie`re, Paris, France

C Lebrun

Department of Neurology, CHU de Nice, Nice, France

T Moreau

Department of Neurology, CHU de Dijon, Dijon, France

P Vermersch

Department of Neurology, CHU de Lille, Lille, France

B Fontaine

Department of Neurology, Hôpital de la Salpêtrie`re, Paris, France

O Lyon-Caen

Department of Neurology, Hôpital de la Salpêtrie`re, Paris, France

O Gout

Department of Neurology, Fondation Ophtalmologique A. de Rothschild, Paris, France

To determine long-term treatment (LTT) of neuromyelitis optica (NMO), we retrospectively reviewed therapies of 26 patients with NMO followed in five French neurological departments. To assess LTT efficacy, the probability of relapse free after LTT was analysed. Patients were divided into two groups according to the first treatment receiving interferon beta (IFN Group, seven patients) or immunosuppressants (IS Group, 19 patients). The probability of relapse was significantly lower in the IS Group (P =0.0007). From our results, interferon beta is not recommended, and one of the best current therapeutic options for NMO appears to be immunosuppressants.

Key Words: beta interferon • immunosuppressive therapy • neuromyelitis optica


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Neurol. Neurosurg. PsychiatryHome page
S Jarius, D Franciotta, R Bergamaschi, S Rauer, K P Wandinger, H F Petereit, M Maurer, H Tumani, A Vincent, P Eichhorn, et al.
Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica
J. Neurol. Neurosurg. Psychiatry, October 1, 2008; 79(10): 1134 - 1136.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
A. Jacob, B. G. Weinshenker, I. Violich, N. McLinskey, L. Krupp, R. J. Fox, D. M. Wingerchuk, M. Boggild, C. S. Constantinescu, A. Miller, et al.
Treatment of Neuromyelitis Optica With Rituximab: Retrospective Analysis of 25 Patients
Arch Neurol, September 8, 2008; (2008) 65.11.noc80069.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
P. Waters, S. Jarius, E. Littleton, M. I. Leite, S. Jacob, B. Gray, R. Geraldes, T. Vale, A. Jacob, J. Palace, et al.
Aquaporin-4 Antibodies in Neuromyelitis Optica and Longitudinally Extensive Transverse Myelitis
Arch Neurol, July 1, 2008; 65(7): 913 - 919.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
J. de Seze, F. Blanc, L. Jeanjean, H. Zephir, P. Labauge, M. Bouyon, L. Ballonzoli, G. Castelnovo, M. Fleury, S. Defoort, et al.
Optical Coherence Tomography in Neuromyelitis Optica
Arch Neurol, July 1, 2008; 65(7): 920 - 923.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. Matiello, V. A. Lennon, A. Jacob, S. J. Pittock, C. F. Lucchinetti, D. M. Wingerchuk, and B. G. Weinshenker
NMO-IgG predicts the outcome of recurrent optic neuritis
Neurology, June 3, 2008; 70(23): 2197 - 2200.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
J. de Seze, C. Arndt, L. Jeanjean, H. Zephir, F. Blanc, P. Labauge, M. Bouyon, L. Ballonzoli, M. Fleury, P. Vermersch, et al.
RELAPSING INFLAMMATORY OPTICNEURITIS: IS IT NEUROMYELITIS OPTICA?
Neurology, May 27, 2008; 70(22): 2075 - 2076.
[Full Text] [PDF]